NCT06014905View on ClinicalTrials.gov

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Meningioma
Interventions
DRUG

Hyperpolarized carbon C 13 pyruvate

Given Intravenously (IV)

PROCEDURE

Magnetic Resonance Image (MRI)

Imaging procedure

OTHER

Saline

Given IV

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

collaborator

General Electric

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Javier Villaneuva-Meyer, MD

OTHER